Compositions and methods for using albumin-based nanomedicines

1. A method of inducing apoptosis, the method comprising:

(i) contacting a population of cells comprising CD20 positive cells with a first conjugate comprising a targeting moiety and a morpholino, wherein the targeting moiety is an anti-CD20 antibody or an anti-CD20 Fab′ fragment; and

(ii) contacting the population of cells with a second conjugate comprising albumin and one or more morpholinos;

wherein the morpholino of the first conjugate is 5′ GAG TAA GCC AAG GAG AAT CAA TAT A 3′ (SEQ ID NO:25) or 5′ TAT ATT GAT TCT CCT TGG CTT ACT C 3′ (SEQ ID NO:26) and wherein the one or more morpholinos of the second conjugate are 5′ GAG TAA GCC AAG GAG AAT CAA TAT A 3′ (SEQ ID NO:25) or 5′ TAT ATT GAT TCT CCT TGG CTT ACT C 3′ (SEQ ID NO:26), wherein the morpholino of the first conjugate and the one or more morpholinos of the second conjugate are complementary,

wherein the contacting of the cells with the first conjugate and the second conjugate induces apoptosis of the CD20 positive cells.

2. The method of claim 1 , further comprising repeating step (i) and step (ii).

3. The method of claim 1 , further comprising (iii) confirming apoptosis of the cells.

4. The method of claim 1 , wherein the CD20 positive cells are B cells.

5. The method of claim 1 , wherein the cells are in a subject.

6. The method of claim 5 , wherein the subject has non-Hodgkin's lymphoma or rheumatoid arthritis.

7. The method of claim 1 , wherein the anti-CD20 receptor antibody is 1F5, rituximab, tositumomab, ibritumomab, ofatumumab, veltuzumab ocrelizumab, ocaratuzumab, obinutuzumab, PRO131921, BCD-020, IBI-301, ublituximab, or BLX-301.

8. The method of claim 1 , wherein the albumin is human serum albumin.

9. A method of inducing apoptosis, the method comprising:

contacting a population of cells comprising CD20 positive cells with a composition comprising

a first conjugate comprising a targeting moiety and a morpholino, wherein the targeting moiety is an anti-CD20 antibody or an anti-CD20 Fab′ fragment and

a second conjugate comprising a conjugate comprising albumin and one or more morpholinos,

wherein the morpholino of the first conjugate is 5′ GAG TAA GCC AAG GAG AAT CAA TAT A 3′ (SEQ ID NO:25) or 5′ TAT ATT GAT TCT CCT TGG CTT ACT C 3′ (SEQ ID NO:26) and wherein the one or more morpholinos of the second conjugate are 5′ GAG TAA GCC AAG GAG AAT CAA TAT A 3′ (SEQ ID NO:25) or 5′ TAT ATT GAT TCT CCT TGG CTT ACT C 3′ (SEQ ID NO:26), wherein the morpholino of the first conjugate and the one or more morpholinos of the second conjugate are complementary,

wherein the contacting of the cells with the composition induces apoptosis of the CD20 positive cells.

10. A kit comprising (i) a first conjugate comprising a targeting moiety and a morpholino, wherein the targeting moiety is an anti-CD20 antibody or an anti-CD20 Fab′ fragment and (ii) a second conjugate comprising albumin and one or more morpholinos,

wherein the morpholino of the first conjugate is 5′ GAG TAA GCC AAG GAG AAT CAA TAT A 3′ (SEQ ID NO:25) or 5′ TAT ATT GAT TCT CCT TGG CTT ACT C 3′ (SEQ ID NO:26) and wherein the one or more morpholinos of the second conjugate are 5′ GAG TAA GCC AAG GAG AAT CAA TAT A 3′ (SEQ ID NO:25) or 5′ TAT ATT GAT TCT CCT TGG CTT ACT C 3′ (SEQ ID NO:26), wherein the morpholino of the first conjugate and the one or more morpholinos of the second conjugate are complementary.

11. The method of claim 9 , further comprising confirming apoptosis of the cells.

12. The method of claim 9 , wherein the CD20 positive cells are B cells.

13. The method of claim 9 , wherein the cells are in a subject.

14. The method of claim 13 , wherein the subject has non-Hodgkin's lymphoma or rheumatoid arthritis.

15. The method of claim 9 , wherein the anti-CD20 receptor antibody is 1F5, rituximab, tositumomab, ibritumomab, ofatumumab, veltuzumab ocrelizumab, ocaratuzumab, obinutuzumab, PRO131921, BCD-020, IBI-301, ublituximab, or BLX-301.

16. The method of claim 9 , wherein the albumin is human serum albumin.